At Singleron Biotechnologies, we are excited to announce the launch of the first commercially available technology that can detect glycosylation together with the whole transcriptome at a single cell level; ProMoSCOPE™.
New facility in Cologne, Germany will serve as a laboratory dedicated to R&D and providing demonstrations on the latest innovative technology for single cell sequencing.
Berlin Science Week 2022 is here! Join us on November 08 at the Berlin Institute of Health at Charité for the Future Medicine Science Match 2022.
Singleron announces the launch of ProMoSCOPE, the first commercially available kit to quantify protein glycosylation at single cell level
We cordially invite you to our educational webinar series focusing on Bioinformatic Analysis of Single Cell Data.
Maleth Program is the first space bioscience project led by Professor Joseph Borg of the University of Malta.
New facility will serve as regional headquarters for Singleron in Asia
Singleron cordially invites you to our free Webinar Miniseries: Single Cell Sequencing for Every Lab.
Singleron further extends reach outside China and strengthens its expertise in translational and clinical research
Understand the basic concepts of the single cell sequencing data analysis
Singleron Biotechnologies recently completed its oversubscribed Series B financing, raising close to $100M.
Join our free webinar to get to know our new fully automated tissue dissociation system!
Discover how to use advanced single-cell multi-omics analysis tools to simultaneously analyze tumor genetic variants and microenvironment
Genomeweb article titled “China's Singleron Biotechnologies Pushes Single-Cell RNA-seq Into Clinical, Translational Studies”
Singleron will present at BioRN conference on October 1st, 2021. Where: Halle02, Zollhofgarten 2, 69115 Heidelberg
October 8-9, 2021 Virtually. "FocuSCOPE: A single cell, multi-omics solution to simultaneously analyze tumor variants and microenvironment"
Singleron will present at CMMC Symposium on September 26-28, 2021 in Cologne
Singleron has raised in A, A1, A2 about $70M in total and introduced prominent investors such as LAV, CDH, ARCH Venture Partners, CDG Capital, and Tencent as new shareholders of the company.
Singleron' products were used in a Covid-study which was recently published in Cell Research on June 16, 2021
Singleron to present two posters at LifeTime conferences.
Copyright © 2024 Singleron Biotechnologies